Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.
Related Questions
How will the addition of Dr. Sinclair and Dr. Goldberg to the advisory board affect the timeline and likelihood of success for ABS-201's clinical trials?
What is the potential market size for a hair loss treatment and how does ABS-201 compare to existing or pipeline competitors?
What are the expected short‑term and long‑term financial impacts on ABSI's valuation and stock price from this development?